Related Experiment Video
Updated: May 7, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice
Cho-Rok Jung1, Jung Hwa Lim, Yoonjung Choi
1Gene Therapy Research Unit, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, South Korea.
Abstract:
The human E3 ubiquitin ligase murine double minute 2 (MDM2) targets the tumor suppressor p53 for ubiquitination and degradation but also promotes its own ubiquitination and subsequent degradation. As the balance between MDM2 and p53 levels plays a crucial role in regulating cell proliferation and apoptosis, we sought to identify factors selectively inhibiting MDM2 self-ubiquitination. Here we have shown that the LIM domain protein Enigma directly interacts with MDM2 to form a ternary complex with p53 in vitro and in human hepatoma and colon carcinoma cell lines and mouse embryonic fibroblasts. We found that Enigma elicited p53 degradation by inhibiting MDM2 self-ubiquitination and increasing its ubiquitin ligase activity toward p53 in cells. Moreover, mitogenic stimuli such as serum, FGF, and HGF increased Enigma transcription via induction of serum response factor (SRF), leading to MDM2 stabilization and subsequent p53 degradation. We observed similar results in the livers of mice treated with HGF. In humans, we found SRF and Enigma coexpressed with MDM2 but not p53 in several liver and stomach tumors. Finally, we showed that Enigma promoted cell survival and chemoresistance by suppressing p53-mediated apoptosis in both cell lines and a mouse xenograft model. Our findings suggest a role for Enigma in tumorigenesis and uncover a mechanism whereby mitogens attenuate p53 antiproliferative activity through an SRF/Enigma/MDM2 pathway.
Insights
The LIM domain protein Enigma inhibits MDM2 self-ubiquitination, promoting p53 degradation. This pathway, regulated by mitogens and SRF, plays a role in tumorigenesis and chemoresistance.
Area of Science:
- Molecular Biology
- Cellular Biology
- Oncology
Background:
- The E3 ubiquitin ligase MDM2 targets tumor suppressor p53 for degradation.
- Maintaining the balance between MDM2 and p53 is critical for cell proliferation and apoptosis.
- Factors inhibiting MDM2 self-ubiquitination are sought to understand cancer regulation.
Purpose of the Study:
- Identify factors that selectively inhibit MDM2 self-ubiquitination.
- Elucidate the role of Enigma in the MDM2/p53 pathway.
- Investigate the link between Enigma, mitogenic stimuli, and tumorigenesis.
Main Methods:
- In vitro and cell line studies using human hepatoma, colon carcinoma, and mouse embryonic fibroblasts.
- Analysis of protein interactions and ubiquitination assays.
- In vivo studies including mouse xenograft models and analysis of human tumor samples.
Main Results:
- Enigma directly interacts with MDM2, forming a ternary complex with p53.
- Enigma inhibits MDM2 self-ubiquitination and enhances MDM2's ligase activity toward p53.
- Mitogenic stimuli (serum, FGF, HGF) induce Enigma transcription via SRF, leading to p53 degradation.
- Enigma promotes cell survival and chemoresistance by suppressing p53-mediated apoptosis.
- SRF and Enigma are coexpressed with MDM2 in human liver and stomach tumors.
Conclusions:
- Enigma plays a role in tumorigenesis by modulating the MDM2/p53 pathway.
- The SRF/Enigma/MDM2 pathway represents a mechanism by which mitogens reduce p53's antiproliferative activity.
- Enigma's function in promoting cell survival and chemoresistance highlights its potential as a therapeutic target.
Related Concept Videos
Negative Regulator Molecules
Epigenetic Regulation
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
DNA Damage Can Stall the Cell Cycle

